Amedeo Smart

Free Medical Literature Service

 

Amedeo

Multiple Sclerosis
  Free Subscription

Articles published in
J Neurol
    May 2026
  1. DE JONG DJ, Molenaar PCG, Verhoef V, Novakova L, et al
    The practice effect of smartphone-derived cognitive processing speed assessments as a proxy of cognitive functioning in multiple sclerosis.
    J Neurol. 2026;273:305.
    >> Share

  2. MAGGI G, Altieri M, d'Ambrosio A, Risi M, et al
    Refining neuropsychological assessment strategies in multiple sclerosis: insights from long-term cognitive trajectories.
    J Neurol. 2026;273:304.
    >> Share

    April 2026
  3. TUOMAALA J, Saraste M, Smith E, Kuusi M, et al
    Association between post-COVID-19 neuropsychiatric symptoms and persistent glial activation in the limbic system: a TSPO PET study.
    J Neurol. 2026;273:298.
    >> Share

  4. PENNER IK, Maier T, Wiemer T, Leemhuis J, et al
    Patient profiling in relapsing multiple sclerosis: insights from a real-world observational study into the unmet medical needs of patients on disease-modifying therapy.
    J Neurol. 2026;273:292.
    >> Share

  5. IND G, Hashmi Z, Ahuja S, Fayad T, et al
    Demyelinating disorders in women: epidemiology, immunology, and clinical implications across MS, NMOSD, and MOGAD.
    J Neurol. 2026;273:290.
    >> Share

  6. AVEDILLO-SALAS A, Martinez LB, Fanlo-Villacampa A, Vicente-Romero J, et al
    Efficacy and safety of monoclonal antibodies in the treatment of relapsing remitting multiple sclerosis: a systematic review.
    J Neurol. 2026;273:286.
    >> Share

  7. BROCHARD V, Lecler A, Januel E, Chaugne E, et al
    Optic chiasmal neuritis: clinical features, aetiologies, MRI patterns and prognosis in a real-world cohort.
    J Neurol. 2026;273:282.
    >> Share

  8. FUCHS TAN, Schoonheim MM, Strijbis EMM, Jelgerhuis JR, et al
    Predicting disease progression in multiple sclerosis with clinically accessible information and technology.
    J Neurol. 2026;273:281.
    >> Share

  9. SUSINNA C, Restuccia G, Triolo G, Marafioti G, et al
    Iron accumulation in multiple sclerosis and implications for cognitive and clinical progression: a systematic review of advanced neuroimaging studies.
    J Neurol. 2026;273:275.
    >> Share

  10. HEGEN H, Fottinger F, Walde J, Berek K, et al
    The role of age in choosing high-efficacy treatment for multiple sclerosis: an Austrian MS Database study.
    J Neurol. 2026;273:262.
    >> Share

  11. JARIUS S, Ruprecht K, Metz I, Konig FB, et al
    An autoantibody signature predictive for multiple sclerosis: evidence at the protein level and association with histopathological lesion types.
    J Neurol. 2026;273:257.
    >> Share

  12. ZIVADINOV R, Semy M, Bartnik A, Hildesheim FE, et al
    Dura mater enhancement on 3T MRI is associated with cortical lesion burden in multiple sclerosis.
    J Neurol. 2026;273:251.
    >> Share

  13. NERI F, Bianchi A, Luchetti L, Breccia D, et al
    Functional head impulse testing for detection and quantification of vestibular dysfunction in multiple sclerosis.
    J Neurol. 2026;273:245.
    >> Share

  14. HAYES MTG, Beadnall HN, Merlo D, Monif M, et al
    Cross-sectional brain volumetric measures and disability outcomes in relapsing-remitting multiple sclerosis.
    J Neurol. 2026;273:243.
    >> Share

  15. GUO J, Olsson T, Johansson E, Alfredsson L, et al
    Long-term disability after initiation of platform versus high-efficacy disease-modifying therapy in relapsing-onset multiple sclerosis.
    J Neurol. 2026;273:240.
    >> Share

    March 2026
  16. MONTALBAN X, Hohlfeld R, Pozzilli C, Freedman MS, et al
    Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.
    J Neurol. 2026;273:234.
    >> Share

  17. MISCIOSCIA A, Silvestri E, Puthenparampil M, Scialpi G, et al
    The cerebellar cognitive affective syndrome scale in early multiple sclerosis.
    J Neurol. 2026;273:219.
    >> Share

  18. WIENDL H, Gold R, Pul R, Ernst M, et al
    Treatment-free remission in MS: long-term disease control with cladribine tablets.
    J Neurol. 2026;273:218.
    >> Share

  19. GUERRA T, Lucisano G, Rocca MA, Cocco E, et al
    HerMeS: a registry-based evaluation of the HERCULES criteria for identifying nonrelapsing SPMS.
    J Neurol. 2026;273:193.
    >> Share

  20. DIMITRIADOU EM, Tzanetakos D, Theodorou A, Akrivaki A, et al
    The predictive value of serum neurofilament light chain in achieving no evidence of disease activity-3 (NEDA-3) status in treatment-naive patients with multiple sclerosis.
    J Neurol. 2026;273:194.
    >> Share

  21. CANDELORO R, Laudisi M, Ferri C, Baldi E, et al
    Beyond oligoclonal bands: the independent role of kappa free light chains in the diagnostic workup of multiple sclerosis.
    J Neurol. 2026;273:191.
    >> Share

  22. FREEDMAN DE, Benedict RHB, Oh J, Feinstein A, et al
    The non-linear relationship between self-reported cognitive concerns and performance-based cognitive dysfunction in people with multiple sclerosis: a cross-sectional study.
    J Neurol. 2026;273:190.
    >> Share

  23. MOLENAAR PCG, de Jong DJ, Hof SN, van Oirschot P, et al
    Digital monitoring of disease activity in relapsing-remitting multiple sclerosis.
    J Neurol. 2026;273:186.
    >> Share

  24. KLEIN KRANENBARG RAM, Blok KM, van Hasselt Y, Melisse S, et al
    Symptoms of depression and anxiety are early predictors of multi-domain disability progression in progressive MS.
    J Neurol. 2026;273:182.
    >> Share

  25. BERGAMASCHI R, Ferraro OE, Enrico P, Marzia F, et al
    Ozone pollution as a possible trigger for multiple sclerosis in young people: the PEDIGREE study.
    J Neurol. 2026;273:172.
    >> Share

    February 2026
  26. SANDROFF BM, Motl RW, Nauman H, Wells GE, et al
    Feasibility of a 12-month, remotely delivered and supported aerobic walking exercise training program for brain and cognition in adults with multiple sclerosis.
    J Neurol. 2026;273:162.
    >> Share

  27. GUO J, Olsson T, Alfredsson L, Hedstrom AK, et al
    Disability progression in multiple sclerosis: a latent class analysis of predictors.
    J Neurol. 2026;273:157.
    >> Share

  28. QU B, Li S, Chen H, Zhang Y, et al
    Disrupted and reorganized connectivity of brain networks in multiple sclerosis: a systematic review and meta-analysis of resting-state functional MRI.
    J Neurol. 2026;273:139.
    >> Share

  29. VAN DEN BOOGAARD LJM, Bochman A, Drenthen GS, Knippenberg SAM, et al
    Longitudinal myelin MR imaging in patients with multiple sclerosis: a narrative review.
    J Neurol. 2026;273:136.
    >> Share

  30. CORSTEN CEA, Geraedts VSA, Marques AM, Melief MJ, et al
    Serum neurofilament light chain and glial fibrillary acidic protein predicting multiple sclerosis after clinically isolated syndrome.
    J Neurol. 2026;273:128.
    >> Share

  31. FREEDMAN DE, Oh J, Feinstein A
    Relationship status and the neurobehavioral symptoms of multiple sclerosis: a cross-sectional analysis.
    J Neurol. 2026;273:126.
    >> Share

  32. GERNERT JA, Zausinger H, Diedrich L, Wicklein R, et al
    The potential of optical coherence tomography angiography in progressive multiple sclerosis.
    J Neurol. 2026;273:118.
    >> Share

  33. GUO J, Olsson T, Alfredsson L, Hedstrom AK, et al
    Patient-reported gradual worsening reveals progression beyond MS subtypes.
    J Neurol. 2026;273:117.
    >> Share

  34. SOUISSI A, Patti F, Spelman T, Chisari C, et al
    Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.
    J Neurol. 2026;273:114.
    >> Share

    January 2026
  35. ZANETTA C, Giordano A, Laserra F, Giliberti A, et al
    Environmental risk factors and conversion to multiple sclerosis in subjects with radiologically isolated syndrome: a case-control study.
    J Neurol. 2026;273:106.
    >> Share

  36. ALADRO Y, Alvarez-Saenz de Tejada C, Diaz-Diaz J, Pilo de la Fuente B, et al
    Prevalence of restless legs syndrome in patients with multiple sclerosis, as confirmed by sleep disorders specialists.
    J Neurol. 2026;273:96.
    >> Share

  37. BAIAMONTE L, Sera F, Bellante G, Ragonese P, et al
    Accuracy of the central vein sign in diagnosis of multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2026;273:95.
    >> Share

  38. GYGER N, Monschein T, Filser M, Batge S, et al
    Cognitive training, exercise training or combined training? A comparative effectiveness research study on subjective and objective cognitive outcomes in multiple sclerosis.
    J Neurol. 2026;273:82.
    >> Share

  39. GRECO G, Della Porta G, Masi F, Redemagni C, et al
    Two-year OCT follow-up in multiple sclerosis patients on Ofatumumab shows retinal preservation over non-antiCD20 treatments.
    J Neurol. 2026;273:77.
    >> Share

    December 2025
  40. YANG J, Li H, Zhang Y, Hu S, et al
    Correction: Effects of exercise on fatigue and quality of life in multiple sclerosis: a network meta-analysis and systematic review.
    J Neurol. 2025;273:51.
    >> Share

  41. CHISARI CG, Lo Fermo S, Di Sapio A, Amato MP, et al
    Effectiveness of Rituximab in rElapsiNg Multiple SclErosis previously treated with hiGhly-Active Disease modifying thErapies (RENEGADE study).
    J Neurol. 2025;273:47.
    >> Share

  42. RESTUCCIA G, Susinna C, Marafioti G, Rifici C, et al
    Serum and cerebrospinal fluid biomarkers as predictors of cognitive impairment in multiple sclerosis: a systematic review of longitudinal studies.
    J Neurol. 2025;273:36.
    >> Share

  43. SURCINELLI A, Massa I, Gentili N, Panzera I, et al
    Harmonized magnetic resonance imaging protocols for multiple sclerosis: HARMONY-MS, a pilot project.
    J Neurol. 2025;273:39.
    >> Share

  44. KONITSIOTI AM, Schweitzer F, Johannis W, Steffen F, et al
    Serum neurofilament light chain as a biomarker of disease control in multiple sclerosis: a real-world cross-sectional analysis of therapeutic regimens.
    J Neurol. 2025;273:34.
    >> Share

  45. TAN H, Yin Z, Zhangbao J, Li X, et al
    Retinal nerve fiber layer thinning in multiple sclerosis: clinical implications, cognitive associations, and effects of disease-modifying therapies.
    J Neurol. 2025;273:25.
    >> Share

  46. BSTEH G, Velez Escola L, Hegen H, Lindner E, et al
    Application of optical coherence tomography in multiple sclerosis: consensus recommendations of the Austrian network (AN-OCT-MS).
    J Neurol. 2025;273:24.
    >> Share

  47. TEDONE N, Preziosa P, Meani A, Mistri D, et al
    Clinical, functional and cognitive features of late-onset multiple sclerosis.
    J Neurol. 2025;273:14.
    >> Share

  48. ELLINGHAUS CA, Rohling HM, Dorsch EM, Sperber PS, et al
    Anchor-based evaluation of digital motor biomarkers from a 2-year observation in 100 patients with multiple sclerosis.
    J Neurol. 2025;273:4.
    >> Share

  49. HEDSTROM AK, Olsson T, Alfredsson L
    Determinants and prognostic value of onset symptoms in multiple sclerosis.
    J Neurol. 2025;273:2.
    >> Share

    November 2025
  50. WANG Z, Li S, Liu J, Li Y, et al
    Nomograms integrating cortical morphometric metrics with 3D multi-parametric MRI radiomics for predicting disability progression and cognitive worsening in relapsing-remitting multiple sclerosis: a multi-center validation study.
    J Neurol. 2025;272:792.
    >> Share

  51. KLEINSCHNITZ C, Skripuletz T, Pfeuffer S, Pawlitzki M, et al
    Is therapy-free remission a realistic goal with cladribine tablets in multiple sclerosis? New insights into the mechanism of action and clinical implications of immune reconstitution with cladribine tablets in MS therapy.
    J Neurol. 2025;272:788.
    >> Share

  52. PIERVINCENZI C, Ojha A, Tommasin S, Satriano F, et al
    Functional connectivity changes are associated with disability progression in multiple sclerosis: a longitudinal fMRI study.
    J Neurol. 2025;272:787.
    >> Share

  53. BALSHI A, Dempsey JP, Kumbar S, Manning N, et al
    Motherhood and diagnostic delay among women with multiple sclerosis.
    J Neurol. 2025;272:784.
    >> Share

  54. YANG X, Li F, Zhe J, Zhang Z, et al
    Single-cell RNA sequencing of cerebrospinal fluid immune cells in relapsing-remitting multiple sclerosis: insights into cellular composition and immune dynamics.
    J Neurol. 2025;272:778.
    >> Share

  55. TEDONE N, Grosselle M, Portaccio E, Amato MP, et al
    The brief repeatable battery of neuropsychological test (BRB-N) version B: update of Italian normative data.
    J Neurol. 2025;272:776.
    >> Share

  56. MONSCHEIN T, Untersteiner H, Ponleitner M, Krajnc N, et al
    Safety of disease-modifying therapies in multiple sclerosis: real-world data from the Austrian MS Treatment Registry (AMSTR).
    J Neurol. 2025;272:774.
    >> Share

  57. MARTIRE MS, Gattuso I, Vezzulli P, Guerrieri S, et al
    Unveiling a silent threat: slowly expanding spinal cord lesion linked to clinical worsening in multiple sclerosis: a case report.
    J Neurol. 2025;272:773.
    >> Share

  58. LADEIRA F, Nobrega C, Cerqueira J
    Correction: Evaluation of the efficacy of the SARS-CoV-2 vaccine additional and booster doses in immunocompromised patients with multiple sclerosis: the COVACiMS study.
    J Neurol. 2025;272:768.
    >> Share

  59. TROJANO M, Iaffaldano P, Copetti M, Drahota J, et al
    Big multiple sclerosis data network: novel modelling approaches for real-world data analysis.
    J Neurol. 2025;272:754.
    >> Share

  60. OZAKBAS S, Alizada S, Caliskan C, Simsek Y, et al
    Familial multiple sclerosis is associated with accelerated progression to secondary progressive phase: a retrospective single-center cohort study.
    J Neurol. 2025;272:749.
    >> Share

  61. WASKOWIAK PT, de Jong BA, Uitdehaag BMJ, Myronenko A, et al
    Cognitive awareness in people with multiple sclerosis before and after neuropsychological assessment.
    J Neurol. 2025;272:748.
    >> Share

  62. MATAS E, Bau L, Romero-Pinel L, Leon I, et al
    Benign multiple sclerosis and long-term outcomes after 30 years.
    J Neurol. 2025;272:747.
    >> Share

    October 2025
  63. MONTE G, Tiralongo G, Papetti L, Ferilli MAN, et al
    Complete Epstein-Barr virus seropositivity in a cohort of pediatric onset multiple sclerosis: a comparison to other autoimmune diseases.
    J Neurol. 2025;272:735.
    >> Share

  64. HUA LH, Brown B, Camacho E, Chinea AR, et al
    Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study.
    J Neurol. 2025;272:725.
    >> Share

  65. ABOSEIF A, Jackson-Tarlton CS, Schwarz CG, Decker PA, et al
    Cervical cord atrophy correlates with intracranial lesion burden in tumefactive multiple sclerosis.
    J Neurol. 2025;272:717.
    >> Share

  66. OPFER R, Spies L, Kruger J, Buddenkotte T, et al
    Whole brain volume loss is associated with a short-term disability progression in relapse-activity free multiple sclerosis.
    J Neurol. 2025;272:715.
    >> Share

  67. SU X, Zheng Z, Yu F, Liu C, et al
    The impact of different exercise types on cognitive function in patients with multiple sclerosis: a systematic review and network meta-analysis.
    J Neurol. 2025;272:709.
    >> Share

  68. PREZIOSA P, Brescia Morra V, Capobianco M, Gasperini C, et al
    Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: current evidence and expert opinion.
    J Neurol. 2025;272:707.
    >> Share

  69. LIU R, Kong L, Cao L, Wang H, et al
    Retinal microvascular differences between multiple sclerosis and neuromyelitis optica spectrum disorder: a cross-sectional study with diagnostic modeling.
    J Neurol. 2025;272:700.
    >> Share

  70. AHMAD R, Jackson-Tarlton CS, Flanagan EP, Messina S, et al
    Critical demyelinating lesions in progressive multiple sclerosis: a prospective observational study.
    J Neurol. 2025;272:677.
    >> Share

    September 2025
  71. WAGSHUL ME, Nayak S, Foley FW, Motl RW, et al
    Grey matter atrophy patterns of mobility shared across older adults with and without multiple sclerosis.
    J Neurol. 2025;272:656.
    >> Share

  72. ROMANO F, Rocca MA, Pagani E, Amato MP, et al
    Effects of cognitive rehabilitation and exercise on brain structure in progressive multiple sclerosis: results from the CogEx trial.
    J Neurol. 2025;272:645.
    >> Share

  73. MORENO-NAVARRO L, Mora-Diaz S, Ruiz-Escribano-Menchen L, Sempere AP, et al
    Kappa free light chain index as a diagnostic and prognostic biomarker in multiple sclerosis.
    J Neurol. 2025;272:646.
    >> Share

  74. HABEK M, Adamec I, Gabelic T, Barun B, et al
    Diagnostic performance of the 2010, 2017, and 2024 McDonald criteria: clinical implications in multiple sclerosis.
    J Neurol. 2025;272:637.
    >> Share

  75. ALONI R, Dror C, Barazani T, Kalron A, et al
    Wartime stress and relapse risk in people with multiple sclerosis: a prospective cohort study.
    J Neurol. 2025;272:619.
    >> Share

  76. YANG J, Li H, Zhang Y, Hu S, et al
    Effects of exercise on fatigue and quality of life in multiple sclerosis: a network meta-analysis and systematic review.
    J Neurol. 2025;272:621.
    >> Share

  77. ELLENBERGER D, Frahm N, Stahmann A, Warnke C, et al
    Age-related differences in switching highly effective disease-modifying therapy in patients with multiple sclerosis.
    J Neurol. 2025;272:609.
    >> Share

  78. ASLAN D, Bourabia S, Kowall B, Straukiene A, et al
    The impact of autoimmune comorbidities on multiple sclerosis progression: insights from a longitudinal single-center study.
    J Neurol. 2025;272:607.
    >> Share

    August 2025
  79. KEVER A, Kang N, Meza C, Pogacar M, et al
    Not for everyone: examining predictors of cognitive rehabilitation success in multiple sclerosis.
    J Neurol. 2025;272:593.
    >> Share

  80. MATHEY G, Epstein J, Alix T, Julien M, et al
    Cerebrospinal fluid levels of chitinase 3-like 1 and interleukin-6 can predict response to platform therapies in relapsing multiple sclerosis.
    J Neurol. 2025;272:592.
    >> Share

  81. ADAMMEK F, Gralla W, Kupjetz M, Rademacher A, et al
    Functional exercise training in persons with multiple sclerosis: a systematic review.
    J Neurol. 2025;272:590.
    >> Share

  82. REEVES JA, Tranquille A, Bartnik A, Mohebbi M, et al
    Paramagnetic rim lesions are associated with choroid plexus inflammation and expansion over 5 years in people with multiple sclerosis.
    J Neurol. 2025;272:585.
    >> Share

  83. SCANDIFFIO J, Langer LK, Senthilnathan V, Feng G, et al
    Effects of psychological therapies in people with multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials.
    J Neurol. 2025;272:584.
    >> Share

  84. GUERRIERI S, Gattuso I, Genchi A, Nozzolillo A, et al
    Stratify and ImmunoWELL JCV tests performances in a real-world multiple sclerosis cohort: possible clinical implications of biosimilar Natalizumab use.
    J Neurol. 2025;272:583.
    >> Share

  85. ABBADESSA G, Maida E, Bonavita S, Lavorgna L, et al
    First the B cells fall, then the T cells follow: temporal immunological shift with ocrelizumab in multiple sclerosis.
    J Neurol. 2025;272:582.
    >> Share

  86. JAWORSKI M 3RD, Balconi J, Santivasci C, Youngs M, et al
    Improving conscientiousness through a smartphone app and telecoaching intervention: insights from multiple sclerosis and healthy aging samples.
    J Neurol. 2025;272:580.
    >> Share

  87. SBAIHAT H, Roenneke K, Muller D, Ladopoulos T, et al
    MRI-based human brain atlases of R1, R2, proton density, and myelin volume fraction using synthetic quantitative imaging at 1.5 T.
    J Neurol. 2025;272:578.
    >> Share

  88. ALFREDSSON L, Guo J, Johansson E, Olsson T, et al
    Early-life and adult body mass index in relation to MS disability progression.
    J Neurol. 2025;272:571.
    >> Share

  89. FILIPPI M, Amato MP, Centonze D, Gallo P, et al
    The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensus.
    J Neurol. 2025;272:565.
    >> Share

  90. LEITNER U, Chew SH, Blanch J, Viswanathan M, et al
    Characteristics of MRI lesions in AQP4 antibody-positive NMOSD, MOGAD, and multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2025;272:560.
    >> Share

  91. MANISCALCO GT, Sparaco M, Di Gregorio M, Cafasso G, et al
    Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study.
    J Neurol. 2025;272:559.
    >> Share

  92. KERITAM O, Ascoli O, Harsanyi A, Cetin H, et al
    Advanced multiple sclerosis: an exploratory study on a neglected patient population.
    J Neurol. 2025;272:553.
    >> Share

  93. MENASCU S, Drori T, Kalron A
    Subcortical brain volume changes linked to concern of falling in multiple sclerosis: a structural MRI study.
    J Neurol. 2025;272:552.
    >> Share

    July 2025
  94. DE SOUZA WAGNER PH, de Paiva FA, Mello JS, Silva ALM, et al
    Clinical outcomes after switching from fingolimod to B-cell-depleting therapies in multiple sclerosis: systematic review and meta-analysis.
    J Neurol. 2025;272:546.
    >> Share

  95. DINI M, Tacchini M, Gamberini G, Boschetti A, et al
    Learning as a digital hallmark of cognition in multiple sclerosis: lessons from a digital symbol digit modalities test.
    J Neurol. 2025;272:536.
    >> Share

  96. FUNG WH, Wessels MHJ, Coerver EME, de Beukelaar J, et al
    Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS).
    J Neurol. 2025;272:530.
    >> Share

  97. VITTURI BK, Cellerino M, Boccia D, Leray E, et al
    Environmental risk factors for multiple sclerosis: a comprehensive systematic review and meta-analysis.
    J Neurol. 2025;272:513.
    >> Share

  98. COLEMAN A, Touze A, Farag M, Pengo M, et al
    Evaluating finger-prick blood collection for remote quantification of neurofilament light in neurological diseases.
    J Neurol. 2025;272:501.
    >> Share

  99. NICOLELLA V, Varelli M, Fasano S, Sirica R, et al
    Clinical application of age-derived cut-offs for plasma neurofilament light chain in multiple sclerosis.
    J Neurol. 2025;272:495.
    >> Share

  100. CAGOL A, Schaedelin S, Ocampo-Pineda M, Benkert P, et al
    Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort.
    J Neurol. 2025;272:491.
    >> Share

    June 2025
  101. ZACCONE T, Moiola L, Guerrieri S, Nozzolillo A, et al
    Long-term effectiveness and safety of ocrelizumab: a single-centre real-world study.
    J Neurol. 2025;272:481.
    >> Share

  102. VERCELLINO M, Marasciulo S, Bosa C, Rolando A, et al
    Added value of spinal cord MRI in detecting active disease in non-relapsing progressive multiple sclerosis patients.
    J Neurol. 2025;272:482.
    >> Share

  103. NAUTA IM, Loughlin KNM, Gravesteijn AS, van Wegen J, et al
    A multi-domain lifestyle intervention in multiple sclerosis: a longitudinal observational study.
    J Neurol. 2025;272:476.
    >> Share

  104. BURGUET VILLENA F, Cerda-Fuertes N, Hofer L, Schadelin S, et al
    Retinal neuronal loss and progression independent of relapse activity in multiple sclerosis.
    J Neurol. 2025;272:454.
    >> Share

  105. ZANETTA C, Gasperini C, Amato MP, Centonze D, et al
    Potential use of the SARS-CoV-2 monoclonal antibody sipavibart in people with multiple sclerosis: definition of different patient archetypes from an Italian expert group perspective.
    J Neurol. 2025;272:446.
    >> Share

  106. CHEN H
    A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS).
    J Neurol. 2025;272:445.
    >> Share

  107. MALUCCHI S, Bava CI, Valentino P, Martire S, et al
    Correction: In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting.
    J Neurol. 2025;272:444.
    >> Share

    May 2025
  108. NEYAL N, Krey KJ, Morrison HA, Nathoo N, et al
    From checkboxes to emojis: a novel approach to patient-reported outcomes in multiple sclerosis.
    J Neurol. 2025;272:434.
    >> Share

  109. CLARELLI F, Corona A, Paakkonen K, Sorosina M, et al
    Correction: Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.
    J Neurol. 2025;272:423.
    >> Share

  110. GASPERINI C, Centonze D, Conte A, Gallo P, et al
    Personalized therapy in multiple sclerosis: an Italian Delphi consensus.
    J Neurol. 2025;272:428.
    >> Share

  111. GIOFRE F, Lugaresi A, Baccari F, Lui E, et al
    The topography of infratentorial lesions in depression and anxiety in multiple sclerosis.
    J Neurol. 2025;272:420.
    >> Share

  112. DAVIES L, Shehadeh R, Watkins WJ, Jolles S, et al
    Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis.
    J Neurol. 2025;272:415.
    >> Share

  113. ZHANG Y, Li G, Su H, Liang Y, et al
    Effects of exercise on balance function in people with multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.
    J Neurol. 2025;272:405.
    >> Share

  114. GERVASONI E, Torchio A, Bertoni R, Chieffo R, et al
    Beyond EDSS: multidomain impairments are detectable and associated with walking disorders in low-disabled people with multiple sclerosis.
    J Neurol. 2025;272:404.
    >> Share

  115. FREEDMAN MS, Abdelhak A, Bhutani MK, Freeman J, et al
    The role of serum neurofilament light (sNfL) as a biomarker in multiple sclerosis: insights from a systematic review.
    J Neurol. 2025;272:400.
    >> Share

  116. TARANU D, Balz LT, Holbrook J, Tumani V, et al
    Cognitive impairment, mood, and fatigue in various multiple sclerosis subtypes: a one-year follow-up study.
    J Neurol. 2025;272:398.
    >> Share

  117. ROCCA MA, Ratzinger S, Preziosa P, Meani A, et al
    Clinical integration of brain and cord MRI features improves differential diagnosis of multiple sclerosis.
    J Neurol. 2025;272:388.
    >> Share

  118. FILIPPI M, Preziosa P, Rocca MA
    Randomized controlled trials for multiple sclerosis: integrating pathology-driven outcomes to capture therapeutic efficacy.
    J Neurol. 2025;272:385.
    >> Share

  119. FREEDMAN DE, Oh J, Einstein G, Feinstein A, et al
    Aging and the neuropsychiatry of multiple sclerosis: a cross-sectional study.
    J Neurol. 2025;272:375.
    >> Share

  120. KOLB H, Shachaf Y, Fainberg K, Golan M, et al
    Intrathecal methotrexate in progressive multiple sclerosis: a phase 1 open-label study with long-term follow-up.
    J Neurol. 2025;272:374.
    >> Share

  121. HERMAN D, Tanniou J, Leray E, Pierret C, et al
    Analyzing recurrent events in multiple sclerosis: a review of statistical models with application to the MSOAC database.
    J Neurol. 2025;272:371.
    >> Share

  122. KUUTTI K, Laakso SM, Viitala M, Atula S, et al
    Mortality and causes of death for people with multiple sclerosis: a Finnish nationwide register study.
    J Neurol. 2025;272:370.
    >> Share

    April 2025
  123. CACCIAGUERRA L, Madhavan A, Sechi E, Krecke KN, et al
    Utility of spinal cord axial-T2 sequence in a population-based cohort of multiple sclerosis.
    J Neurol. 2025;272:367.
    >> Share

  124. MAHMOUDI N, Renne J, Konen FF, Jendretzky KF, et al
    Added value of optic nerve lesions for multiple sclerosis diagnostic criteria.
    J Neurol. 2025;272:358.
    >> Share

  125. LEAVITT V, Mostert J, Comtois J, Moral E, et al
    Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy.
    J Neurol. 2025;272:338.
    >> Share

  126. BALSHI A, Dempsey J, Kumbar S, Leuenberger G, et al
    Correction: Marriage is associated with decreased lesion volumes and less brain atrophy in people with multiple sclerosis.
    J Neurol. 2025;272:337.
    >> Share

  127. OJHA A, Tommasin S, Piervincenzi C, Baione V, et al
    Clinical and MRI features contributing to the clinico-radiological dissociation in a large cohort of people with multiple sclerosis.
    J Neurol. 2025;272:327.
    >> Share

  128. HONG J, Gaubert M, Lefort M, Ferre JC, et al
    Limited added value of systematic spinal cord MRI vs brain MRI alone to classify patients with MS as active or inactive during follow-up.
    J Neurol. 2025;272:316.
    >> Share

  129. MOIOLA L, Mandelli A, Tarkowski M, Finardi A, et al
    Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab.
    J Neurol. 2025;272:314.
    >> Share

  130. LADOPOULOS T, Abbas Z, Krieger B, Bellenberg B, et al
    Neurological disability and brain grey matter atrophy in primary progressive multiple sclerosis are determined by microstructural lesional changes, but not by lesion load.
    J Neurol. 2025;272:302.
    >> Share

    March 2025
  131. KONITSIOTI AM, Laurent S, Ellenberger D, Stahmann A, et al
    MS treatment trends before, during, and after the COVID-19 pandemic: insights from the German MS Register.
    J Neurol. 2025;272:294.
    >> Share

  132. LADEIRA F, Nobrega C, Cerqueira J
    Evaluation of the efficacy of the SARS-CoV-2 vaccine additional and booster doses in immunocompromised patients with multiple sclerosis: the COVACiMS study.
    J Neurol. 2025;272:288.
    >> Share

  133. BOSTAN M, Li C, Cheong JW, Wong DWK, et al
    Longitudinal analysis of retinal and choriocapillaris in patients with multiple sclerosis: a 3-year study.
    J Neurol. 2025;272:237.
    >> Share

    February 2025
  134. AZZIMONTI M, Preziosa P, Pagani E, Meani A, et al
    Cervical spinal cord gray matter damage predicts disability worsening in multiple sclerosis: a longitudinal study.
    J Neurol. 2025;272:228.
    >> Share

  135. SCHONHERR C, Ziegler J, Zentek T, Rashid A, et al
    Smartphone-based gait analysis in the assessment of fatigue and fatigability in people with multiple sclerosis: a supervised cohort study.
    J Neurol. 2025;272:217.
    >> Share

  136. BALSHI A, Dempsey J, Manning N, Leuenberger G, et al
    A disproportionality analysis of surgical site infections across multiple sclerosis disease modifying therapies.
    J Neurol. 2025;272:223.
    >> Share

  137. NAYAK S, Wagshul ME, Foley FW, Motl RW, et al
    Associations between connectivity in functional brain networks and gait speed in older adults with and without multiple sclerosis.
    J Neurol. 2025;272:216.
    >> Share

  138. DI SABATINO E, Ferraro D, Gaetani L, Emiliano E, et al
    CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective.
    J Neurol. 2025;272:211.
    >> Share

  139. MARASTONI D, Sicchieri M, Pizzini FB, Scartezzini A, et al
    Multiple sclerosis diagnosis and its differential diagnosis in patients presenting with type four 'mirror pattern' CSF oligoclonal bands.
    J Neurol. 2025;272:207.
    >> Share

  140. FILIPPI M, Amato MP, Avolio C, Gallo P, et al
    Towards a biological view of multiple sclerosis from early subtle to clinical progression: an expert opinion.
    J Neurol. 2025;272:179.
    >> Share

    January 2025
  141. GIANNOPAPAS V, Smyrni V, Kitsos DK, Stefanou MI, et al
    Cancer in multiple sclerosis patients following prolonged exposure to disease-modifying therapies (DMTs): a systematic review and meta-analysis.
    J Neurol. 2025;272:162.
    >> Share

  142. INOJOSA H, Schriefer D, Ness NH, Dillenseger A, et al
    Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study.
    J Neurol. 2025;272:153.
    >> Share

  143. PIHL-JENSEN G, Frederiksen JL
    The value of magnetic resonance imaging of the optic nerve for the diagnosis of multiple sclerosis in patients with optic neuritis.
    J Neurol. 2025;272:131.
    >> Share

  144. LAGEMAN SB, Jolly A, Sahi N, Prados F, et al
    Explaining cognitive function in multiple sclerosis through networks of grey and white matter features: a joint independent component analysis.
    J Neurol. 2025;272:142.
    >> Share

  145. MIRMOSAYYEB O, Weinstock-Guttman B, Zivadinov R, Jakimovski D, et al
    Anatomy-driven segmentation of parafoveal optical coherence tomography (OCT) measures may improve associations with clinical outcomes in multiple sclerosis.
    J Neurol. 2025;272:141.
    >> Share

  146. BALSHI A, Dempsey J, Kumbar S, Leunberger G, et al
    Marriage is associated with decreased lesion volumes and less brain atrophy in people with multiple sclerosis.
    J Neurol. 2025;272:151.
    >> Share

  147. MAR S, Valeriani M, Steinborn B, Schreiner T, et al
    Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study.
    J Neurol. 2025;272:137.
    >> Share

  148. MAIWORM M, Koerbel K, Anschutz V, Jakob J, et al
    BDNF levels in serum and CSF are associated with clinicoradiological characteristics of aggressive disease in MS patients.
    J Neurol. 2025;272:147.
    >> Share

  149. PREZIOSA P, Pagani E, Meani A, Margoni M, et al
    Soma and neurite density abnormalities of paramagnetic rim lesions and core-sign lesions in multiple sclerosis.
    J Neurol. 2025;272:145.
    >> Share

  150. PLESS S, Woelfle T, Lorscheider J, Wiencierz A, et al
    CoGames: Development of an adaptive smartphone-based and gamified monitoring tool for cognitive function in Multiple Sclerosis.
    J Neurol. 2025;272:119.
    >> Share

  151. ZANGHI A, Greco A, Giancipoli E, Tumani H, et al
    Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer.
    J Neurol. 2025;272:109.
    >> Share

  152. ROBERTSON NP
    Bruton's tyrosine kinase inhibitor for multiple sclerosis: new hope or false dawn.
    J Neurol. 2025;272:106.
    >> Share

  153. WALBAUM M, Madhukar A, Dobson R, Cyhlarova E, et al
    Cost effectiveness of different treatment strategies with natalizumab for pregnant women with multiple sclerosis.
    J Neurol. 2025;272:93.
    >> Share

  154. FILIPPI M, Gallo P, Gasperini C, Marfia GA, et al
    Implementing proximity care for people with multiple sclerosis in Italy: the bottom-up approach of the StayHome project.
    J Neurol. 2025;272:96.
    >> Share

    December 2024
  155. NICOLESCU M, Haussler V, Paul F, Oertel FC, et al
    Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision.
    J Neurol. 2024;272:86.
    >> Share

  156. BARBA L, Gaetani L, Sperandei S, Di Sabatino E, et al
    CSF synaptic biomarkers and cognitive impairment in multiple sclerosis.
    J Neurol. 2024;272:85.
    >> Share

  157. MIRMOSAYYEB O, Yazdan Panah M, Moases Ghaffary E, Vaheb S, et al
    Magnetic resonance imaging-based biomarkers of multiple sclerosis and neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
    J Neurol. 2024;272:77.
    >> Share

  158. FILIPPI M, Margoni M, Zaccone T, Guerrieri S, et al
    Disability worsening outcome in multiple sclerosis based on EDSS: does half a point matter?
    J Neurol. 2024;272:9.
    >> Share

  159. VECCHIO D, Puricelli C, Virgilio E, Passarelli F, et al
    Kappa index for multiple sclerosis diagnosis: an accurate biomarker of intrathecal synthesis.
    J Neurol. 2024;272:30.
    >> Share

  160. PONZIO M, Santoni L, Molina M, Tavazzi E, et al
    Economic burden of multiple sclerosis in an Italian cohort of patients on disease-modifying therapy: analysis of disease cost and its components.
    J Neurol. 2024;272:50.
    >> Share

  161. DE BLASIIS P, Massimiani A, Inglese C, Bianchini E, et al
    Spasticity patterns assessment and recognition for therapeutic approaches (SPARTA) in multiple sclerosis: a multicenter epidemiological study.
    J Neurol. 2024;272:34.
    >> Share

  162. GASPERINI C, Battaglia MA, Balzani F, Chiarini E, et al
    Unveiling preferences in multiple sclerosis care: insights from an Italian discrete-choice experiment with patients and healthcare professionals.
    J Neurol. 2024;272:27.
    >> Share

  163. COMABELLA M, Hegen H, Villar LM, Rejdak K, et al
    Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis.
    J Neurol. 2024;272:26.
    >> Share

    November 2024
  164. PAKEERATHAN T, Havla J, Schwake C, Salmen A, et al
    Rapid differentiation of MOGAD and MS after a single optic neuritis.
    J Neurol. 2024;271:7222-7231.
    >> Share

    October 2024
  165. FACCIORUSSO S, Malfitano C, Giordano M, Del Furia MJ, et al
    Effectiveness of robotic rehabilitation for gait and balance in people with multiple sclerosis: a systematic review.
    J Neurol. 2024 Oct 10. doi: 10.1007/s00415-024-12715.
    >> Share

  166. SELMAJ K, Hartung HP, Mycko MP, Selmaj I, et al
    MS treatment de-escalation: review and commentary.
    J Neurol. 2024;271:6426-6438.
    >> Share

    September 2024
  167. MALUCCHI S, Bava CI, Valentino P, Martire S, et al
    In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting.
    J Neurol. 2024 Sep 23. doi: 10.1007/s00415-024-12701.
    >> Share

  168. MARGONI M, Valsasina P, Moiola L, Mistri D, et al
    Monoaminergic network abnormalities are associated with fatigue in pediatric multiple sclerosis.
    J Neurol. 2024 Sep 19. doi: 10.1007/s00415-024-12689.
    >> Share

  169. YOUSEF H, Malagurski Tortei B, Castiglione F
    Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review.
    J Neurol. 2024 Sep 12. doi: 10.1007/s00415-024-12651.
    >> Share

  170. CLARELLI F, Corona A, Paakkonen K, Sorosina M, et al
    Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.
    J Neurol. 2024 Sep 12. doi: 10.1007/s00415-024-12608.
    >> Share

  171. CALLEN AM, Zurawski J, Chu R, Tie Y, et al
    The role of 7 T MRI to assess atrophy of the subcortical deep gray matter in relapsing-remitting multiple sclerosis.
    J Neurol. 2024 Sep 6. doi: 10.1007/s00415-024-12656.
    >> Share

  172. DELUCA J
    Correction to: Fatigue in multiple sclerosis: can we measure it and can we treat it?
    J Neurol. 2024 Sep 6. doi: 10.1007/s00415-024-12630.
    >> Share

  173. PORTACCIO E, Betti M, De Meo E, Addazio I, et al
    Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
    J Neurol. 2024 Sep 4. doi: 10.1007/s00415-024-12627.
    >> Share

  174. GIOSSI R, Mercenari M, Filippi M, Zanetta C, et al
    Correction to: Unprescribed cannabinoids and multiple sclerosis: a multicenter, cross-sectional, epidemiological study in Lombardy, Italy.
    J Neurol. 2024 Sep 3. doi: 10.1007/s00415-024-12560.
    >> Share

    August 2024
  175. WURDACK K, Pruss H, Finke C
    Evolution from viral encephalitis to autoimmune encephalitis to multiple sclerosis: a case report.
    J Neurol. 2024 Aug 31. doi: 10.1007/s00415-024-12659.
    >> Share

  176. CHISARI CG, Amato MP, Di Sapio A, Foschi M, et al
    Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA).
    J Neurol. 2024 Aug 27. doi: 10.1007/s00415-024-12621.
    >> Share

  177. CAROTENUTO A, Di Monaco C, Papetti L, Borriello G, et al
    Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod.
    J Neurol. 2024 Aug 23. doi: 10.1007/s00415-024-12610.
    >> Share

  178. SIMONE M, Lucisano G, Guerra T, Paolicelli D, et al
    Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis.
    J Neurol. 2024 Aug 23. doi: 10.1007/s00415-024-12638.
    >> Share

  179. MISCIOSCIA A, Mainero C, Treaba CA, Silvestri E, et al
    The contribution of paramagnetic rim and cortical lesions to physical and cognitive disability at multiple sclerosis clinical onset: evaluating the power of MRI and OCT biomarkers.
    J Neurol. 2024 Aug 19. doi: 10.1007/s00415-024-12622.
    >> Share

  180. ARNETT SV, Prain K, Ramanathan S, Bhuta S, et al
    Long-term outcomes of ADEM-like and tumefactive presentations of CNS demyelination: a case-comparison analysis.
    J Neurol. 2024;271:5275-5289.
    >> Share

  181. ZIVADINOV R, Jakimovski D, Burnham A, Kuhle J, et al
    Neuroimaging assessment of facility-bound severely-affected MS reveals the critical role of cortical gray matter pathology: results from the CASA-MS case-controlled study.
    J Neurol. 2024;271:4949-4962.
    >> Share

    July 2024
  182. FILIPPI M, Pagani E, Turrini R, Bartezaghi M, et al
    Effects of fingolimod on focal and diffuse damage in patients with relapsing-remitting multiple sclerosis - The "EVOLUTION" study.
    J Neurol. 2024 Jul 29. doi: 10.1007/s00415-024-12590.
    >> Share

  183. MANZANO GS, Levy M, Salky R, Mateen FJ, et al
    Assessment of international MOGAD diagnostic criteria in patients with overlapping MOG-associated disease and multiple sclerosis phenotypes.
    J Neurol. 2024 Jul 27. doi: 10.1007/s00415-024-12585.
    >> Share

  184. PASSALI M, Galea I, Knudsen MH, Lau LC, et al
    Cerebrospinal fluid neurofilament light chain in acute optic neuritis and its predictive ability of multiple sclerosis.
    J Neurol. 2024 Jul 25. doi: 10.1007/s00415-024-12587.
    >> Share

  185. KARL AS, Klimas R, Katsimpoura M, Sgodzai M, et al
    Quality of life and tolerability of B-cell directed therapy of multiple sclerosis with ofatumumab in a patient-centered real-world observational study.
    J Neurol. 2024 Jul 22. doi: 10.1007/s00415-024-12581.
    >> Share

  186. MOLENAAR PCG, Noteboom S, van Nederpelt DR, Krijnen EA, et al
    Digital outcome measures are associated with brain atrophy in patients with multiple sclerosis.
    J Neurol. 2024 Jul 15. doi: 10.1007/s00415-024-12516.
    >> Share

  187. RAVANO V, Andelova M, Piredda GF, Sommer S, et al
    Microstructural characterization of multiple sclerosis lesion phenotypes using multiparametric longitudinal analysis.
    J Neurol. 2024 Jul 13. doi: 10.1007/s00415-024-12568.
    >> Share

  188. VITI V, Zanetta C, Capra R, Municchi A, et al
    Ocrelizumab-associated enteritis in patients with multiple sclerosis: an emerging safety issue.
    J Neurol. 2024 Jul 11. doi: 10.1007/s00415-024-12553.
    >> Share

  189. DELUCA J
    Fatigue in multiple sclerosis: can we measure it and can we treat it?
    J Neurol. 2024 Jul 5. doi: 10.1007/s00415-024-12524.
    >> Share

  190. ROT U, Jerala M, Horvat Ledinek A, Brecl Jakob G, et al
    Progressive multifocal leukoencephalopathy in association with siponimod treatment for secondary progressive multiple sclerosis: a case report.
    J Neurol. 2024 Jul 3. doi: 10.1007/s00415-024-12542.
    >> Share

  191. KAPPOS L, Edan G, Freedman MS, Hartung HP, et al
    Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.
    J Neurol. 2024;271:4599-4609.
    >> Share

  192. ZANGHI A, Borriello G, Bonavita S, Fantozzi R, et al
    Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study.
    J Neurol. 2024;271:4495-4502.
    >> Share

  193. HARTUNG HP, Berger T, Bermel RA, Brochet B, et al
    ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.
    J Neurol. 2024;271:4348-4360.
    >> Share

  194. MAKHANI N, Lebrun-Frenay C, Siva A, Shabanova V, et al
    The diagnostic workup of children with the radiologically isolated syndrome differs by age and by sex.
    J Neurol. 2024;271:4019-4027.
    >> Share

    June 2024
  195. LAL AP, Foong YC, Sanfilippo PG, Spelman T, et al
    A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.
    J Neurol. 2024 Jun 27. doi: 10.1007/s00415-024-12518.
    >> Share

  196. NOTEBOOM S, Seiler M, Chien C, Rane RP, et al
    Evaluation of machine learning-based classification of clinical impairment and prediction of clinical worsening in multiple sclerosis.
    J Neurol. 2024 Jun 23. doi: 10.1007/s00415-024-12507.
    >> Share

  197. SIMANI L, Molaeipour L, Kian S, Leavitt VM, et al
    Correlation between cognitive changes and neuroradiological changes over time in multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2024 Jun 18. doi: 10.1007/s00415-024-12517.
    >> Share

  198. GIOSSI R, Mercenari M, Filippi M, Zanetta C, et al
    Unprescribed cannabinoids and multiple sclerosis: a multicenter, cross-sectional, epidemiological study in Lombardy, Italy.
    J Neurol. 2024 Jun 7. doi: 10.1007/s00415-024-12472.
    >> Share

    May 2024
  199. PORTACCIO E, Betti M, De Meo E, Addazio I, et al
    Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
    J Neurol. 2024 May 28. doi: 10.1007/s00415-024-12448.
    >> Share

  200. MONTEIRO I, Nicolella V, Fiorenza M, Novarella F, et al
    The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis.
    J Neurol. 2024 May 23. doi: 10.1007/s00415-024-12434.
    >> Share

  201. CORTESE R, Battaglini M, Stromillo ML, Luchetti L, et al
    Regional hippocampal atrophy reflects memory impairment in patients with early relapsing remitting multiple sclerosis.
    J Neurol. 2024 May 14. doi: 10.1007/s00415-024-12290.
    >> Share

  202. WOLF E, Wicklein R, Aly L, Schmaderer C, et al
    Optical coherence tomography angiography suggests different retinal pathologies in multiple sclerosis and Sjogren's syndrome.
    J Neurol. 2024 May 14. doi: 10.1007/s00415-024-12414.
    >> Share

  203. FREEDMAN DE, Oh J, Kiss A, Puopolo J, et al
    The influence of depression and anxiety on cognition in people with multiple sclerosis: a cross-sectional analysis.
    J Neurol. 2024 May 11. doi: 10.1007/s00415-024-12409.
    >> Share

  204. BARDEL B, Creange A, Bonardet N, Bapst B, et al
    Motor function in multiple sclerosis assessed by navigated transcranial magnetic stimulation mapping.
    J Neurol. 2024 May 6. doi: 10.1007/s00415-024-12398.
    >> Share

  205. GALPERIN I, Buzaglo D, Gazit E, Shimoni N, et al
    Gait and heart rate: do they measure trait or state physical fatigue in people with multiple sclerosis?
    J Neurol. 2024 May 2. doi: 10.1007/s00415-024-12339.
    >> Share

  206. ROCCA MA, Romano F, Tedone N, Filippi M, et al
    Advanced neuroimaging techniques to explore the effects of motor and cognitive rehabilitation in multiple sclerosis.
    J Neurol. 2024 May 1. doi: 10.1007/s00415-024-12395.
    >> Share

  207. PREZIOSA P, Rocca MA, Filippi M
    Radiologically isolated syndromes: to treat or not to treat?
    J Neurol. 2024;271:2370-2378.
    >> Share

    April 2024
  208. DIMAURO KA, Swetlik C, Cohen JA
    Management of multiple sclerosis in older adults: review of current evidence and future perspectives.
    J Neurol. 2024 Apr 30. doi: 10.1007/s00415-024-12384.
    >> Share

  209. ROSENSTEIN I, Nordin A, Sabir H, Malmestrom C, et al
    Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis.
    J Neurol. 2024 Apr 26. doi: 10.1007/s00415-024-12389.
    >> Share

  210. NAUTA IM, van Dam M, Bertens D, Kessels RPC, et al
    Improved quality of life and psychological symptoms following mindfulness and cognitive rehabilitation in multiple sclerosis and their mediating role for cognition: a randomized controlled trial.
    J Neurol. 2024 Apr 23. doi: 10.1007/s00415-024-12327.
    >> Share

  211. SPIEZIA AL, Scalia G, Petracca M, Caliendo D, et al
    Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications.
    J Neurol. 2024 Apr 17. doi: 10.1007/s00415-024-12362.
    >> Share

  212. HIRT J, Dembowska K, Woelfle T, Axfors C, et al
    Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis.
    J Neurol. 2024 Apr 16. doi: 10.1007/s00415-024-12366.
    >> Share

  213. SINGER BA, Feng J, Chiong-Rivero H
    Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.
    J Neurol. 2024 Apr 14. doi: 10.1007/s00415-024-12305.
    >> Share

  214. STALTER J, Pars K, Witt K
    Accelerated long-term forgetting reveals everyday memory deficits in early-stage multiple sclerosis.
    J Neurol. 2024 Apr 8. doi: 10.1007/s00415-024-12359.
    >> Share

  215. CELIK M, Baba C, Irmak C, Ozakbas S, et al
    Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey.
    J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12333.
    >> Share

  216. STEFANOU MI, Giannopapas V, Kitsos DK, Chondrogianni M, et al
    Prevalence and epidemiology of stroke in patients with multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2024 Apr 4. doi: 10.1007/s00415-024-12331.
    >> Share

  217. MAIDA E, Moccia M, Palladino R, Borriello G, et al
    ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis.
    J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12328.
    >> Share

  218. SIGNORIELLO E, Foschi M, Lanzillo R, Frau J, et al
    Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine.
    J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12291.
    >> Share

  219. GUERRIERI S, Rubin M, Gattuso I, Zanetta C, et al
    Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series.
    J Neurol. 2024 Apr 2. doi: 10.1007/s00415-024-12342.
    >> Share

  220. TEDONE N, Vizzino C, Meani A, Gallo A, et al
    The brief repeatable battery of neuropsychological tests (BRB-N) version a: update of Italian normative data from the Italian Neuroimaging Network Initiative (INNI).
    J Neurol. 2024;271:1813-1823.
    >> Share

  221. GLASER A, Butzkueven H, van der Walt A, Gray O, et al
    Big Multiple Sclerosis Data network: an international registry research network.
    J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12303.
    >> Share

  222. HUA T, Fan H, Duan Y, Tian D, et al
    Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis.
    J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12281.
    >> Share

    March 2024
  223. GUILLEMIN C, Vandeleene N, Charonitis M, Requier F, et al
    Brain microstructure is linked to cognitive fatigue in early multiple sclerosis.
    J Neurol. 2024 Mar 28. doi: 10.1007/s00415-024-12316.
    >> Share

  224. SCHALLER-PAULE MA, Maiworm M, Schafer JH, Friedauer L, et al
    Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
    J Neurol. 2024 Mar 27. doi: 10.1007/s00415-024-12299.
    >> Share

  225. MALLUCCI G, Ferraro OE, Trojano M, Amato MP, et al
    Early prediction of unfavorable evolution after a first clinical episode suggestive of multiple sclerosis: the EUMUS score.
    J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12304.
    >> Share

  226. PILOTTO S, Floris M, Solla P, Pugliatti M, et al
    Determinants of self-perceived quality of life in mildly disabled multiple sclerosis patients: a cross-sectional study.
    J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12244.
    >> Share

  227. GOERECI Y, Ellenberger D, Rommer P, Dunkl V, et al
    Persons with multiple sclerosis older than 55 years: an analysis from the German MS registry.
    J Neurol. 2024 Mar 22. doi: 10.1007/s00415-024-12286.
    >> Share

  228. ALBERGONI M, Pagani E, Preziosa P, Meani A, et al
    Thalamic nuclei volume partially mediates the effects of aerobic capacity on fatigue in people with multiple sclerosis.
    J Neurol. 2024 Mar 20. doi: 10.1007/s00415-024-12277.
    >> Share

  229. ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
    Correction to: The impact of metformin use on the outcomes of relapse?remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open?label randomized controlled trial.
    J Neurol. 2024 Mar 18. doi: 10.1007/s00415-024-12249.
    >> Share

  230. KRIJNEN EA, Broeders TAA, Noteboom S, van Dam M, et al
    The cognitive relevance of non-lesional damage to cortical networks in people with multiple sclerosis.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12240.
    >> Share

  231. HEGEN H, Berek K, Deisenhammer F, Berger T, et al
    Sex impacts treatment decisions in multiple sclerosis.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12270.
    >> Share

  232. HECHENBERGER S, Helmlinger B, Tinauer C, Jauk E, et al
    Evaluation of a self-administered iPad((R))-based processing speed assessment for people with multiple sclerosis in a clinical routine setting.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12274.
    >> Share

  233. ZID Y, Robertson NP
    Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials.
    J Neurol. 2024 Mar 4. doi: 10.1007/s00415-024-12273.
    >> Share

  234. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
    Early intensive versus escalation treatment in patients with relapsing-remitting multiple sclerosis in Austria.
    J Neurol. 2024 Mar 2. doi: 10.1007/s00415-024-12256.
    >> Share

    February 2024
  235. SCHERER L, Soudant M, Pittion-Vouyovitch S, Debouverie M, et al
    Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study.
    J Neurol. 2024 Feb 29. doi: 10.1007/s00415-024-12266.
    >> Share

  236. TOLJAN K, Briggs FBS
    Male sexual and reproductive health in multiple sclerosis: a scoping review.
    J Neurol. 2024 Feb 28. doi: 10.1007/s00415-024-12250.
    >> Share

  237. LEAVITT VM, Tozlu C, Nelson KE, Boehme AK, et al
    A randomized controlled trial of oral antipyretic treatment to reduce overheating during exercise in adults with multiple sclerosis.
    J Neurol. 2024 Feb 28. doi: 10.1007/s00415-023-12147.
    >> Share

  238. VAN DAM M, Krijnen EA, Nauta IM, Fuchs TA, et al
    Identifying and understanding cognitive profiles in multiple sclerosis: a role for visuospatial memory functioning.
    J Neurol. 2024 Feb 26. doi: 10.1007/s00415-024-12227.
    >> Share

  239. CUTILLO G, Rubin M, d'Amore G, Malcangi M, et al
    Infratentorial posterior reversible encephalopathy syndrome in INFbeta1a-treated multiple sclerosis patient.
    J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12226.
    >> Share

  240. BIANCHI A, Matranga D, Patti F, Maniscalco L, et al
    The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT).
    J Neurol. 2024 Feb 16. doi: 10.1007/s00415-024-12214.
    >> Share

  241. HARDING KE, Kreft KL, Ben-Shlomo Y, Robertson NP, et al
    Prodromal multiple sclerosis: considerations and future utility.
    J Neurol. 2024 Feb 11. doi: 10.1007/s00415-023-12173.
    >> Share

    January 2024
  242. BAJRAMI A, Tamanti A, Peloso A, Ziccardi S, et al
    Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis.
    J Neurol. 2024 Jan 30. doi: 10.1007/s00415-023-12179.
    >> Share

  243. BOUMAN PM, van Dam MA, Jonkman LE, Steenwijk MD, et al
    Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI patterns and its development over time.
    J Neurol. 2024 Jan 30. doi: 10.1007/s00415-024-12185.
    >> Share

  244. NAUTA IM, Kessels RPC, Bertens D, Stam CJ, et al
    Neurophysiological brain function predicts response to cognitive rehabilitation and mindfulness in multiple sclerosis: a randomized trial.
    J Neurol. 2024 Jan 26. doi: 10.1007/s00415-024-12183.
    >> Share

  245. FENG G, Posa S, Sureshkumar A, Simpson S, et al
    Experiences of people with multiple sclerosis and clinicians in using cognitive behavioural therapies for hidden symptoms: a systematic review and meta-aggregation.
    J Neurol. 2024 Jan 14. doi: 10.1007/s00415-023-12116.
    >> Share

  246. ZHENG P, Sandroff BM, Motl RW
    Free-living ambulatory physical activity and cognitive function in multiple sclerosis: the significance of step rate vs. step volume.
    J Neurol. 2024 Jan 12. doi: 10.1007/s00415-023-12169.
    >> Share

  247. MAILLART E, Todesco E, Assoumou L, Beigneux Y, et al
    Humoral response after accelerated schedule of HBV vaccination in MS patients before anti-CD20 therapy.
    J Neurol. 2024 Jan 11. doi: 10.1007/s00415-023-12175.
    >> Share

  248. TRYFONOS C, Chrysafi M, Vadikolias K, Berberoglou L, et al
    Nutritional interventional studies in patients with multiple sclerosis: a scoping review of the current clinical evidence.
    J Neurol. 2024 Jan 4. doi: 10.1007/s00415-023-12140.
    >> Share

  249. LOREFICE L, Ferraro OE, Fenu G, Amato MP, et al
    Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry.
    J Neurol. 2024 Jan 3. doi: 10.1007/s00415-023-12152.
    >> Share

  250. MOSER T, Zimmermann G, Baumgartner A, Berger T, et al
    Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study.
    J Neurol. 2024;271:374-385.
    >> Share

    December 2023
  251. AZZIMONTI M, Margoni M, Zanetta C, Genovese F, et al
    Tumefactive demyelinating lesions: a challenging first manifestation of multiple sclerosis.
    J Neurol. 2023 Dec 28. doi: 10.1007/s00415-023-12164.
    >> Share

  252. IAFFALDANO P, Lucisano G, Guerra T, Patti F, et al
    Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.
    J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12137.
    >> Share

  253. ANDORRA M, Freire A, Zubizarreta I, de Rosbo NK, et al
    Predicting disease severity in multiple sclerosis using multimodal data and machine learning.
    J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12132.
    >> Share

  254. MISTRI D, Valsasina P, Storelli L, Filippi M, et al
    Monoaminergic network dysfunction and development of depression in multiple sclerosis: a longitudinal investigation.
    J Neurol. 2023 Dec 19. doi: 10.1007/s00415-023-12138.
    >> Share

  255. HABBESTAD A, Willumsen JS, Aarseth JH, Grytten N, et al
    Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study.
    J Neurol. 2023 Dec 14. doi: 10.1007/s00415-023-12047.
    >> Share

  256. COVEY TJ, Golan D, Sergott R, Wilken J, et al
    Peering further into the mind's eye: combining visual evoked potential and optical coherence tomography measures enhances insight into the variance in cognitive functioning in multiple sclerosis.
    J Neurol. 2023 Dec 13. doi: 10.1007/s00415-023-12075.
    >> Share

  257. ARROYO PEREIRO P, Munoz-Vendrell A, Leon Moreno I, Bau L, et al
    Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
    J Neurol. 2023 Dec 12. doi: 10.1007/s00415-023-12135.
    >> Share

  258. TSAI CC, Jette S, Tremlett H
    Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic review.
    J Neurol. 2023 Dec 11. doi: 10.1007/s00415-023-12107.
    >> Share

  259. ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
    The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial.
    J Neurol. 2023 Dec 9. doi: 10.1007/s00415-023-12113.
    >> Share

    November 2023
  260. MEYER-ARNDT L, Brasanac J, Gamradt S, Bellmann-Strobl J, et al
    Body mass, neuro-hormonal stress processing, and disease activity in lean to obese people with multiple sclerosis.
    J Neurol. 2023 Nov 27. doi: 10.1007/s00415-023-12100.
    >> Share

  261. MISTRI D, Tedone N, Biondi D, Vizzino C, et al
    Cognitive phenotypes in multiple sclerosis: mapping the spectrum of impairment.
    J Neurol. 2023 Nov 26. doi: 10.1007/s00415-023-12102.
    >> Share

  262. JAKIMOVSKI D, Kavak KS, Coyle PK, Goodman AD, et al
    Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
    J Neurol. 2023 Nov 23. doi: 10.1007/s00415-023-12099.
    >> Share

  263. BISECCO A, Matrone F, Capobianco M, De Luca G, et al
    COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
    J Neurol. 2023 Nov 20. doi: 10.1007/s00415-023-12084.
    >> Share

  264. KENNEDY PGE, George W, Yu X
    The elusive nature of the oligoclonal bands in multiple sclerosis.
    J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12081.
    >> Share

  265. DI FILIPPO M, Ferraro D, Ragonese P, Prosperini L, et al
    SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.
    J Neurol. 2023 Nov 3. doi: 10.1007/s00415-023-12034.
    >> Share

  266. FROHLICH K, Mrochen A, Wang R, Haupenthal D, et al
    Cerebral lesions sites in neurosarcoidosis: a lesion mapping study.
    J Neurol. 2023;270:5392-5397.
    >> Share

  267. JEANTIN L, Shor N, Pallix-Guyot M, Roos-Weil D, et al
    Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod.
    J Neurol. 2023 Nov 1. doi: 10.1007/s00415-023-12055.
    >> Share

    October 2023
  268. MANTERO V, Cordano C, Balgera R, Basilico P, et al
    Serum sickness in a multiple sclerosis patient treated with ocrelizumab.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12082.
    >> Share

  269. KAPPOS L, Traboulsee A, Li DKB, Bar-Or A, et al
    Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-11943.
    >> Share

  270. DELGADO SR, Faissner S, Linker RA, Rammohan K, et al
    Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12007.
    >> Share

  271. RIVEL M, Achiron A, Stern Y, Zeilig G, et al
    Emotional burden among MS patients: associations between specific chronic pain diagnoses and psychological features.
    J Neurol. 2023 Oct 24. doi: 10.1007/s00415-023-12048.
    >> Share

  272. ONTANEDA D, Chitnis T, Rammohan K, Obeidat AZ, et al
    Identification and management of subclinical disease activity in early multiple sclerosis: a review.
    J Neurol. 2023 Oct 21. doi: 10.1007/s00415-023-12021.
    >> Share

  273. ZINGANELL A, Gobel G, Berek K, Hofer B, et al
    Multiple sclerosis in the elderly: a retrospective cohort study.
    J Neurol. 2023 Oct 19. doi: 10.1007/s00415-023-12041.
    >> Share

  274. SELMAJ K, Cree BAC, Barnett M, Thompson A, et al
    Multiple sclerosis: time for early treatment with high-efficacy drugs.
    J Neurol. 2023 Oct 18. doi: 10.1007/s00415-023-11969.
    >> Share

  275. RAVANO V, Piredda GF, Krasensky J, Andelova M, et al
    Tract-wise microstructural analysis informs on current and future disability in early multiple sclerosis.
    J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-12023.
    >> Share

    September 2023
  276. RODRIGUEZ DE VERA GOMEZ P, Mendez Muros M, Torres Cuadro A, Toyos Saenz de Miera FJ, et al
    Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis.
    J Neurol. 2023 Sep 29. doi: 10.1007/s00415-023-11995.
    >> Share

  277. LI Y, Saul A, Taylor B, Ponsonby AL, et al
    Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
    J Neurol. 2023 Sep 28. doi: 10.1007/s00415-023-11980.
    >> Share

  278. WEEDA MM, van Nederpelt DR, Twisk JWR, Brouwer I, et al
    Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis.
    J Neurol. 2023 Sep 17. doi: 10.1007/s00415-023-11937.
    >> Share

  279. FILIPPI M, Grimaldi L, Conte A, Totaro R, et al
    Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.
    J Neurol. 2023 Sep 16. doi: 10.1007/s00415-023-11955.
    >> Share

  280. MCARTHUR C, Daruwalla C, Jayeskara M, Brown JWL, et al
    Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis.
    J Neurol. 2023 Sep 12. doi: 10.1007/s00415-023-11984.
    >> Share

  281. JACOBS BM, Tank P, Bestwick JP, Noyce AJ, et al
    Modifiable risk factors for multiple sclerosis have consistent directions of effect across diverse ethnic backgrounds: a nested case-control study in an English population-based cohort.
    J Neurol. 2023 Sep 7. doi: 10.1007/s00415-023-11971.
    >> Share

    August 2023
  282. FERRAND M, Epstein J, Soudant M, Guillemin F, et al
    Real-life evaluation of the 2017 McDonald criteria for relapsing-remitting multiple sclerosis after a clinically isolated syndrome confirms a gain in time-to-diagnosis.
    J Neurol. 2023 Aug 31. doi: 10.1007/s00415-023-11905.
    >> Share

  283. BONACCHI R, Valsasina P, Pagani E, Meani A, et al
    Sex-related differences in upper limb motor function in healthy subjects and multiple sclerosis patients: a multiparametric MRI study.
    J Neurol. 2023 Aug 28. doi: 10.1007/s00415-023-11948.
    >> Share

  284. TOSCANO S, Chisari CG, Lo Fermo S, Gulino G, et al
    A dynamic interpretation of kappaFLC index for the diagnosis of multiple sclerosis: a change of perspective.
    J Neurol. 2023 Aug 28. doi: 10.1007/s00415-023-11952.
    >> Share

  285. JAKIMOVSKI D, Zivadinov R, Weinstock Z, Fuchs TA, et al
    Cortical thickness and cognition in older people with multiple sclerosis.
    J Neurol. 2023 Aug 27. doi: 10.1007/s00415-023-11945.
    >> Share

  286. SPIERER R, Lavi I, Bloch S, Mazar M, et al
    Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies.
    J Neurol. 2023 Aug 17. doi: 10.1007/s00415-023-11935.
    >> Share

  287. KLETENIK I, Cohen AL, Glanz BI, Ferguson MA, et al
    Multiple sclerosis lesions that impair memory map to a connected memory circuit.
    J Neurol. 2023 Aug 2. doi: 10.1007/s00415-023-11907.
    >> Share

    July 2023
  288. TILSLEY P, Strohmeyer IA, Heinrich I, Rosenthal F, et al
    Correction to: Physical fitness moderates the association between brain network impairment and both motor function and cognition in progressive multiple sclerosis.
    J Neurol. 2023 Jul 26. doi: 10.1007/s00415-023-11874.
    >> Share

  289. NOTEBOOM S, van Nederpelt DR, Bajrami A, Moraal B, et al
    Feasibility of detecting atrophy relevant for disability and cognition in multiple sclerosis using 3D-FLAIR.
    J Neurol. 2023 Jul 19. doi: 10.1007/s00415-023-11870.
    >> Share

  290. ROCCA MA, Valsasina P, Lamanna MT, Colombo B, et al
    Functional connectivity modifications in monoaminergic circuits occur in fatigued MS patients treated with fampridine and amantadine.
    J Neurol. 2023 Jul 18. doi: 10.1007/s00415-023-11858.
    >> Share

  291. LOMBARDO-DEL TORO P, Bragado-Trigo I, Arroyo P, Tena-Cucala R, et al
    Fingolimod-associated progressive multifocal leukoencephalopathy in a multiple sclerosis patient with a good response to filgrastim.
    J Neurol. 2023 Jul 17. doi: 10.1007/s00415-023-11865.
    >> Share

  292. PETROU P, Achiron A, Cohen EG, Garty M, et al
    Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group‏ Viewpoint.
    J Neurol. 2023 Jul 12. doi: 10.1007/s00415-023-11846.
    >> Share

  293. AMATO MP, Bergamaschi R, Centonze D, Mirabella M, et al
    Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study.
    J Neurol. 2023 Jul 5. doi: 10.1007/s00415-023-11820.
    >> Share

  294. NICULAE AS, Niculae LE, Vacaras C, Vacaras V, et al
    Serum levels of neurofilament light chains in pediatric multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2023 Jul 2. doi: 10.1007/s00415-023-11841.
    >> Share

  295. JARIUS S, Aktas O, Ayzenberg I, Bellmann-Strobl J, et al
    Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
    J Neurol. 2023;270:3341-3368.
    >> Share

    June 2023
  296. RUGGIERI S, Prosperini L, Petracca M, Logoteta A, et al
    The added value of spinal cord lesions to disability accrual in multiple sclerosis.
    J Neurol. 2023 Jun 29. doi: 10.1007/s00415-023-11829.
    >> Share

  297. TILSLEY P, Strohmeyer IA, Heinrich I, Rosenthal F, et al
    Physical fitness moderates the association between brain network impairment and both motor function and cognition in progressive multiple sclerosis.
    J Neurol. 2023 Jun 21. doi: 10.1007/s00415-023-11806.
    >> Share

  298. ROSENSTEIN I, Axelsson M, Novakova L, Malmestrom C, et al
    Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple sclerosis.
    J Neurol. 2023 Jun 14. doi: 10.1007/s00415-023-11817.
    >> Share

  299. GRANGE E, Solaro C, Di Giovanni R, Marengo D, et al
    The correlation between 9-HPT and patient-reported measures of upper limb function in multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2023 Jun 9. doi: 10.1007/s00415-023-11801.
    >> Share

  300. MONSCHEIN T, Dekany S, Zrzavy T, Ponleitner M, et al
    Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
    J Neurol. 2023 Jun 5. doi: 10.1007/s00415-023-11784.
    >> Share

  301. HOLTZER R, Choi J, Motl RW, Foley FW, et al
    Individual reserve in aging and neurological disease.
    J Neurol. 2023;270:3179-3191.
    >> Share

    May 2023
  302. LOUAPRE C, Rosenzwajg M, Golse M, Roux A, et al
    A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis.
    J Neurol. 2023 May 28. doi: 10.1007/s00415-023-11690.
    >> Share

  303. AZZIMONTI M, Preziosa P, Pagani E, Valsasina P, et al
    Functional and structural brain MRI changes associated with cognitive worsening in multiple sclerosis: a 3-year longitudinal study.
    J Neurol. 2023 May 18. doi: 10.1007/s00415-023-11778.
    >> Share

  304. ZANETTA C, Rocca MA, Meani A, Martinelli V, et al
    Correction to: Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
    J Neurol. 2023 May 17. doi: 10.1007/s00415-023-11772.
    >> Share

  305. MUNOZ-VENDRELL A, Arroyo-Pereiro P, Leon I, Bau L, et al
    Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment.
    J Neurol. 2023;270:2559-2566.
    >> Share

    April 2023
  306. KREMMYDA O, Feil K, Bardins S, Strupp M, et al
    Acetyl-DL-leucine in combination with memantine improves acquired pendular nystagmus caused by multiple sclerosis: a case report.
    J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11730.
    >> Share

  307. VAN DAM M, de Jong BA, Willemse EAJ, Nauta IM, et al
    A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort.
    J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11676.
    >> Share

  308. MARGONI M, Pagani E, Preziosa P, Gueye M, et al
    Unraveling the heterogeneous pathological substrates of relapse-onset multiple sclerosis: a multiparametric voxel-wise 3 T MRI study.
    J Neurol. 2023 Apr 24. doi: 10.1007/s00415-023-11736.
    >> Share

  309. KOUTSOURAKI E, Theodoros K, Eleni G, Marianna K, et al
    Autonomic nervous system disorders in multiple sclerosis.
    J Neurol. 2023 Apr 21. doi: 10.1007/s00415-023-11725.
    >> Share

  310. MONSCHEIN T, Dekany S, Zrzavy T, Ponleitner M, et al
    Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
    J Neurol. 2023 Apr 19. doi: 10.1007/s00415-023-11686.
    >> Share

  311. GANAPATHY SUBRAMANIAN R, Zivadinov R, Bergsland N, Dwyer MG, et al
    Multiple sclerosis optic neuritis and trans-synaptic pathology on cortical thinning in people with multiple sclerosis.
    J Neurol. 2023 Apr 17. doi: 10.1007/s00415-023-11709.
    >> Share

  312. YEO T, Siew RWE, Gulam MY, Tye JSN, et al
    COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore.
    J Neurol. 2023 Apr 7:1-9. doi: 10.1007/s00415-023-11692.
    >> Share

  313. ZANETTA C, Rocca MA, Meani A, Martinelli V, et al
    Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
    J Neurol. 2023 Apr 7:1-12. doi: 10.1007/s00415-023-11700.
    >> Share

  314. VRENKEN H, Battaglini M, de Vos ML, Nagtegaal GJ, et al
    Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon beta-1a.
    J Neurol. 2023;270:2271-2282.
    >> Share

  315. LEHTO J, Sucksdorff M, Nylund M, Raitanen R, et al
    PET-measurable innate immune cell activation reduction in chronic active lesions in PPMS brain after rituximab treatment: a case report.
    J Neurol. 2023;270:2329-2332.
    >> Share

  316. ASTBURY L, Kalra S, Tanasescu R, Constantinescu CS, et al
    CSF lymphocytic pleocytosis does not predict a less favourable long-term prognosis in MS.
    J Neurol. 2023;270:2042-2047.
    >> Share

    March 2023
  317. PLESS S, Woelfle T, Naegelin Y, Lorscheider J, et al
    Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study.
    J Neurol. 2023 Mar 23. doi: 10.1007/s00415-023-11671.
    >> Share

  318. TORRES P, Sancho-Saldana A, Gil Sanchez A, Peralta S, et al
    A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
    J Neurol. 2023 Mar 18:1-12. doi: 10.1007/s00415-023-11575.
    >> Share

  319. ROMANO F, Motl RW, Valsasina P, Amato MP, et al
    Abnormal thalamic functional connectivity correlates with cardiorespiratory fitness and physical activity in progressive multiple sclerosis.
    J Neurol. 2023 Mar 18. doi: 10.1007/s00415-023-11664.
    >> Share

  320. DE ROSA AP, Esposito F, Valsasina P, d'Ambrosio A, et al
    Correction to: Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative.
    J Neurol. 2023 Mar 13. doi: 10.1007/s00415-023-11646.
    >> Share

  321. MOGAVERO MP, Lanza G, Bruni O, DelRosso LM, et al
    Sleep counts! Role and impact of sleep in the multimodal management of multiple sclerosis.
    J Neurol. 2023 Mar 11. doi: 10.1007/s00415-023-11655.
    >> Share

  322. VELDKAMP R, D'hooge M, Sandroff BM, DeLuca J, et al
    Profiling cognitive-motor interference in a large sample of persons with progressive multiple sclerosis and impaired processing speed: results from the CogEx study.
    J Neurol. 2023 Mar 7. doi: 10.1007/s00415-023-11636.
    >> Share

  323. LI G, You Q, Hou X, Zhang S, et al
    The effect of exercise on cognitive function in people with multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.
    J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11649.
    >> Share

  324. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
    Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing-remitting multiple sclerosis in Austria.
    J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11644.
    >> Share

  325. BARLETTA VT, Herranz E, Treaba CA, Mehndiratta A, et al
    In vivo characterization of microglia and myelin relation in multiple sclerosis by combined (11)C-PBR28 PET and synthetic MRI.
    J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11621.
    >> Share

  326. DIETMANN AS, Kruse N, Stork L, Gloth M, et al
    Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study.
    J Neurol. 2023;270:1416-1429.
    >> Share

    February 2023
  327. BAETGE SJ, Filser M, Renner A, Raithel LM, et al
    Supporting brain health in multiple sclerosis: exploring the potential of neuroeducation combined with practical mindfulness exercises in the management of neuropsychological symptoms.
    J Neurol. 2023 Feb 25:1-14. doi: 10.1007/s00415-023-11616.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016